High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone
about
Hypoglycemic agents and potential anti-inflammatory activityPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.A Prospective Study of Variability in Glycemic Control during Different Phases of the Menstrual Cycle in Type 2 Diabetic Women Using High Sensitivity C - Reactive Protein.Is there any association of personality traits with vascular endothelial function or systemic inflammation?Inflammatory biomarker C-reactive protein and radiotherapy-induced early adverse skin reactions in patients with breast cancer.Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapPioglitazone in the treatment of type 2 diabetes: safety and efficacy reviewInfluence of atherosclerosis-related risk factors on serum high-sensitivity C-reactive protein levels in patients with type 2 diabetes: Comparison of their influence in obese and non-obese patients.Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitusEffects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial.Is there any association of anxiety-depressive symptoms with vascular endothelial function or systemic inflammation?Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.Inflammatory mediators involved in the progression of the metabolic syndrome.The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.Macrophage migration inhibitory factor (MIF) enhances palmitic acid- and glucose-induced murine beta cell dysfunction and destruction in vitro.Oxidized Low Density Lipoprotein and High Sensitive C-Reactive Protein in Non-Diabetic, Pre-Diabetic and Diabetic Patients in the Acute Phase of the First Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention.Effect of folic acid and vitamin B12 on the expression of PPARγ, caspase-3 and caspase-8 mRNA in the abdominal aortas of rats with hyperlipidemia.Impact of adenotonsillectomy on high-sensitivity C-reactive protein levels in obese children with obstructive sleep apnea.Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.A molecular case-control study of association of HNF1A gene polymorphisms (rs2259816 and rs7310409) with risk of coronary artery disease in Iranian patients.Microalbuminuria predicts silent myocardial ischaemia in type 2 diabetes patients.Pioglitazone abolishes autistic-like behaviors via the IL-6 pathway.Circulating levels of adipose tissue-derived inflammatory factors in elderly diabetes patients with carotid atherosclerosis: a retrospective study.The Clinical Significance and Potential Role of C-Reactive Protein in Chronic Inflammatory and Neurodegenerative Diseases.
P2860
Q26750414-365CF622-B4F0-46A0-8438-44D304AED972Q30597265-8B7D2FF9-E960-405B-92F9-0CD27C7FBFCEQ33783447-6FC5418A-291F-4132-9F26-36B90949A5E9Q34447729-5A4B4F43-ABEB-4515-A3FC-172D019CB4C1Q34970929-4FF50FB6-A39A-4F08-924F-753B38E66CEDQ35178857-36528F59-80A8-4FAF-82C0-69B2959011BCQ36139056-1BED421B-A629-4A02-8EE1-73453177CDBEQ36637949-F8E95A95-8B18-4B8A-8E14-EB060A59FDCBQ36785475-4205215C-1669-45C0-BC1C-B2413E657E0AQ36845012-AE514D4F-77F2-460C-956D-595D8E8D959FQ37531933-96A78243-6E06-4929-8A1D-8187343C2F18Q37794960-28702330-E2D4-41E3-BD07-586A99306DDBQ37990459-95463828-E483-4277-A970-5E38303406C2Q38593722-3EA901BF-3D4A-4AE8-9ECB-7E9B0878795EQ39247779-1F6B0AD4-2647-4144-99F3-DE3BB5FE16E9Q42240864-521C3859-072D-4C6F-BD6F-B0FB182DEE62Q42541628-5CE85A75-3EC1-4AA4-9CBA-143391636F53Q43931223-EC4F122F-D0AD-4E89-8C14-7E04240F028BQ47697775-3F7ADD1B-729B-43DD-AE43-E44B1F675C7AQ50880534-EA44EEEF-E013-40A1-9591-FFFD429D6618Q53124913-92E8AD94-5ECE-4B0E-A3A1-57BFAE2F386FQ54201255-607E0737-22E0-4E72-8FDF-000F48A6ADE9Q55073204-AA67DC8E-EAB1-492D-9534-9D93FE071A38Q55373841-CDBEDCEB-BA7C-44B7-A024-21F233CC82B9
P2860
High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
High-sensitivity C-reactive pr ...... ng treatment with pioglitazone
@ast
High-sensitivity C-reactive pr ...... ng treatment with pioglitazone
@en
type
label
High-sensitivity C-reactive pr ...... ng treatment with pioglitazone
@ast
High-sensitivity C-reactive pr ...... ng treatment with pioglitazone
@en
prefLabel
High-sensitivity C-reactive pr ...... ng treatment with pioglitazone
@ast
High-sensitivity C-reactive pr ...... ng treatment with pioglitazone
@en
P2860
P1476
High-sensitivity C-reactive pr ...... ng treatment with pioglitazone
@en
P2093
Thomas Forst
Thomas Schöndorf
P2860
P304
P356
10.1177/193229681000400326
P577
2010-05-01T00:00:00Z